N/A N=121 Somatosensory Modulation of Salivary Gene Expression and Oral Feeding in Preterm Infants
Infant, Extremely Low Birth Weight · Feeding Behavior
Primary: Salivary Gene Expression — 21.344; 21.420; 20.931; 21.100 Delta-CT — p=<0.01
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=95 Adolescent Depression Screening and Treatment in Mozambican Primary Care
Depression · Adolescent Behavior
Primary: Change in PHQ-A Score From Baseline to 6 Months Post-intervention — -35.9; -54.0 percent change
Phase 2 N=24 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants
Gram-negative Bacterial Infections · Bloodstream Infections (BSI) · Complicated Intra-abdominal Infection (cIAI)
Primary: Single-Dose Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 0; 1; 3; 1 Participants
N/A N=218 Safety and Efficacy of SINOMED SR for Endovascular Treatment of Acute Ischemic Stroke
Ischemic Stroke, Acute · Brain Diseases · Cerebrovascular Disorders
Primary: Number of Participants With Successful Immediate Recanalization — 105; 103 participants
Phase 4 N=180 Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
Relapse Remitting Multiple Sclerosis
Primary: Percentage of Participants Achieving NEDA-3 (No Evidence of Disease Activity-3) — 81.1 percentage of participants
N/A N=77 Stress, Emotion Regulation, and Alcohol in Women Veterans
Alcohol Use Disorder · Post Traumatic Stress Disorder
Primary: Change in Alcohol Craving During Experimental Sessions — 2.87; 2.97; 3.18; 3.22 Units on a Scale — p=.94
N/A N=245 QuitBet Phase II: A Digital Social Game That Pays You to Stop Smoking
Smoking Cessation
Primary: Number of Participants Who Reported no Cigarette Smoking During the Past 7 Days — 30; 35 Participants
N/A N=294,878 Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol
Gout
Primary: Time to Dementia Onset — 14.44; 18.23; 22.07; 19.40 Incidence rate per 1000 person year
N/A N=277 Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin
Community-acquired Pneumonia
Primary: Vancomycin-free Hours Alive — 105.7; 109.7 Hours
N/A N=56 Sleep Treatment Education Program for Young Adult Cancer Survivors (STEP-YA)
Insomnia · Insomnia Due to Medical Condition · Cancer
Primary: Insomnia Severity Change at 8 Weeks — 7.25; 5.67 Units on a scale
N/A N=48 Randomized Controlled Trial of CES for Fibromyalgia
Fibromyalgia
Primary: Clinical Pain Change — -0.97; -1.75; -1.38; -2.00 Change (from baseline) in DVPRS score
N/A N=601 CBTpro: Scaling up CBT for Psychosis Using Simulated Patients and Spoken Language Technologies
Psychosis · Schizophrenia · Schizo Affective Disorder
Primary: Revised Green Paranoid Thoughts Scale (R-GPTS) Mean Score — 12.1; 12.3; 12.1; 11.4 Score on a Scale
N/A N=500 Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes
Bloodstream Infection · Sepsis Bacterial · MRSA Bacteremia
Primary: Time to Last Dose of Intravenous Vancomycin — 19.0; 12.5 time in hours
N/A N=14 Low-Cost Platelet-Rich Plasma for Hemarthropathy
Hemarthrosis · Hemophilia
Primary: Global Satisfaction (Numeric Rating System) — 70 Scores on a scale
N/A N=178 Efficiency and Safety of Holmium Laser With Moses Technology Versus SuperPulsed Laser System With Thulium Fiber Laser on Renal Stones
Renal Stone
Primary: Stone Free Rate — 36; 34 Participants